Market Cap 447.62B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.86
Forward PE 17.75
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 1,948,643
Avg Vol 7,321,322
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 96%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
NasdaqAlpha
NasdaqAlpha Jun. 30 at 3:57 PM
$ABBV has taken some heat after the recent trial headlines, but I don't think the whole pipeline should be judged on one update. The market tends to swing between optimism and disappointment with biotech, while the longer-term picture usually takes much more time to play out. I'm watching how investors respond after the dust settles rather than reacting to a single headline.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:09 PM
$SLS $GILD $ABBV Great Day to BUY $SLS Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:04 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH. 60th Event / Share Price Launch 72nd Event / Share Price Launch 78th Event / Share Price Launch 80th Event / Share Price Will Be Launching IMMINENTLY. Just Look at the Market Action Since the 60th Event, when the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - from the Ongoing P3. - Share Price 10x, Market Cap +12X Cash on Hand up 10x Runway to 2030, Institutional Funds from 39 to 167 - not 1 Short only. Smarter Money than US Knows Gps is Golden.
0 · Reply
Oldpuck
Oldpuck Jun. 30 at 2:59 PM
$ABBV Rotation didn't last very long
0 · Reply
NasdaqFrontier
NasdaqFrontier Jun. 30 at 2:56 PM
$ABBV is making waves with the latest phase 3 results and aggressive M&A strategy. I wasn't expecting such a steady reaction to the acquisition news, but it seems the market is focused on the long-term pipeline strength. Still, I’m not chasing the current level. Stalking this base to see if it holds support before I even consider adding to the position.
0 · Reply
Blockwave1
Blockwave1 Jun. 30 at 2:44 PM
Telegram channel: https://t.me/BlockWave10 $ABBV $QQQ $SPY $AAPL remembers this guy? 😂🔥 He’s been absolutely crushing the setups! The trust and consistency have been incredible, and I truly appreciate the support. 💯 I’ll keep doing my part and bringing the best opportunities. Much love to everyone who’s been rocking with us! ❤️🌊
0 · Reply
NvidiaKing
NvidiaKing Jun. 30 at 2:02 PM
$ABBV this is a POS 🐓
0 · Reply
Quantumup
Quantumup Jun. 30 at 11:13 AM
Guggenheim reiterated Best Idea $ABVX at Buy-$175 SYRE CRVS PALI PTGX - $JNJ APGE - $ABBV RHHBY MRK TEVA Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2071914563683901822?s=20
0 · Reply
Quantumup
Quantumup Jun. 30 at 10:24 AM
BTIG⬆️ $ABVX-$175,⬆️PoS for obefazimod in UC to 95% & CD to 85% and reiterated at Buy PTGX - $JNJ APGE - $ABBV SYRE PALI RHHBY MRK TEVA Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2071902283541999785?s=20
0 · Reply
notreload_ai
notreload_ai Jun. 30 at 9:00 AM
$ABBV, $GMAB new drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy. https://notreload.xyz/xy/abbvie-genmab-positive-phase-3-results-in-r-r-dlbcl/
0 · Reply
Latest News on ABBV
AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 4 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 6 days ago

AbbVie's $11 Billion Immunology Bet

APGE


Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 7 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE


AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 7 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE


AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 7 days ago

AbbVie announces European Commission approval for Skyrizi


AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 7 days ago

AbbVie announces European Commission approval of Maviret


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 8 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 11 days ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


NasdaqAlpha
NasdaqAlpha Jun. 30 at 3:57 PM
$ABBV has taken some heat after the recent trial headlines, but I don't think the whole pipeline should be judged on one update. The market tends to swing between optimism and disappointment with biotech, while the longer-term picture usually takes much more time to play out. I'm watching how investors respond after the dust settles rather than reacting to a single headline.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:09 PM
$SLS $GILD $ABBV Great Day to BUY $SLS Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:04 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH. 60th Event / Share Price Launch 72nd Event / Share Price Launch 78th Event / Share Price Launch 80th Event / Share Price Will Be Launching IMMINENTLY. Just Look at the Market Action Since the 60th Event, when the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - from the Ongoing P3. - Share Price 10x, Market Cap +12X Cash on Hand up 10x Runway to 2030, Institutional Funds from 39 to 167 - not 1 Short only. Smarter Money than US Knows Gps is Golden.
0 · Reply
Oldpuck
Oldpuck Jun. 30 at 2:59 PM
$ABBV Rotation didn't last very long
0 · Reply
NasdaqFrontier
NasdaqFrontier Jun. 30 at 2:56 PM
$ABBV is making waves with the latest phase 3 results and aggressive M&A strategy. I wasn't expecting such a steady reaction to the acquisition news, but it seems the market is focused on the long-term pipeline strength. Still, I’m not chasing the current level. Stalking this base to see if it holds support before I even consider adding to the position.
0 · Reply
Blockwave1
Blockwave1 Jun. 30 at 2:44 PM
Telegram channel: https://t.me/BlockWave10 $ABBV $QQQ $SPY $AAPL remembers this guy? 😂🔥 He’s been absolutely crushing the setups! The trust and consistency have been incredible, and I truly appreciate the support. 💯 I’ll keep doing my part and bringing the best opportunities. Much love to everyone who’s been rocking with us! ❤️🌊
0 · Reply
NvidiaKing
NvidiaKing Jun. 30 at 2:02 PM
$ABBV this is a POS 🐓
0 · Reply
Quantumup
Quantumup Jun. 30 at 11:13 AM
Guggenheim reiterated Best Idea $ABVX at Buy-$175 SYRE CRVS PALI PTGX - $JNJ APGE - $ABBV RHHBY MRK TEVA Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2071914563683901822?s=20
0 · Reply
Quantumup
Quantumup Jun. 30 at 10:24 AM
BTIG⬆️ $ABVX-$175,⬆️PoS for obefazimod in UC to 95% & CD to 85% and reiterated at Buy PTGX - $JNJ APGE - $ABBV SYRE PALI RHHBY MRK TEVA Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2071902283541999785?s=20
0 · Reply
notreload_ai
notreload_ai Jun. 30 at 9:00 AM
$ABBV, $GMAB new drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy. https://notreload.xyz/xy/abbvie-genmab-positive-phase-3-results-in-r-r-dlbcl/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 3:55 AM
$SLS $GILD $ABBV r/gabri71 deep cut In conclusions the Authors state ‘The longer OS observed in patients who subsequently underwent allo-HSCT refrains the fact that stem cell transplantation after the achievement of a CR/CRi is still the only viable, and possibly curative, option for patients with r/R AML (and this was around 20 months of mOS after reaching CR2 status)’. 20 month MOS FOR CR2 getting transplant, 8.8 month MOS for CR2 not getting Transplant, on BAT. https://www.reddit.com/r/sellaslifesciences/s/dWtZbCNCoh
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 30 at 3:47 AM
$ABBV $BMY $LLY $PFE $SLS BIG MOVES IN BIOTECH INNOVATION IS MERGING. SLS Next up. ✌️🙏❤️‍🩹
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 30 at 3:23 AM
$ABBV Current Stock Price: $254.22 Contracts to trade: $255.0 ABBV Jul 02 2026 Call Entry: $2.21 Exit: $3.04 ROI: 37% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 1:47 AM
$SLS $LLY $PFE $ABBV $BMY SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Announces-Positive-Phase-2-Preliminary-Data-of-SLS009-in-rr-AML-Achieving-a-100-Response-Rate-in-Patients-with-ASXL1-Mutation-At-the-Optimal-Dose-Level/default.aspx
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 30 at 12:40 AM
$SLS $LLY $PFE $ABBV $BMY Kelonia is still in Phase 1, so durability is the open question. So Why did Lilly pay $7B for a cancer therapy with 18 treated patients? At ASCO, Kelonia reported 100% response. Kelonia developed an in vivo CAR-T for multiple myeloma - and the ASCO update is genuinely strong: every patient responded, the first treated remains in deep remission past 10 months, and safety has held so far. Why Lilly paid $7B. Today's standard CAR-T is ex vivo: harvest a patient's cells, engineer them in a lab, precondition with chemo, and reinfuse. It's very expensive, slow, and gated by manufacturing. In vivo CAR-T is off-the-shelf - a one-time injection, no chemo prep, and a fraction of the cost. Know what you own, GPS Regal Pivotal Registrational is a Phase 3 pre commercialization ready Platform for 20+ WT1 cancers with CURATIVE outcome, 0 Safety issues, 0 Toxicity, off the shelf not a complex Biologic= $240.00+
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 12:27 AM
$SLS $GILD $ABBV Aza+VEN, Best Available Treatment (BAT) for Control ARM Patients, Recently FAILED 4 Large Phase 3 AML Remission Maintenance Trials conducted by $ABBV and MDACC.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 30 at 12:02 AM
$SLS Is any day now a long time wait for a 10x to 20x + ROI ? 5 years in the making Now as Imminent as Imminent Gets Keep in Mind -- While we continue to wait for near miraculous extended Survival, in a Transplant Ineligible, Post Salvage, Second Remission AML patient setting, who have a "high risk of Leukemic Relapse and most of whom harbour measurable residual disease", Aza+VEN BAT for Control ARM Patients, Recently Failed 4 Large Phase 3 AML Remission Maintenance Trials conducted by $ABBV and MDACC.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 11:48 PM
$SLS $GILD $ABBV - Dec 8th 2024 - 60th Event PR Launched the Share Price - Jan 23rd 2025 - IDMC Unblinded Actual Phase 3 MOS and IR Data from the 60th Event Interim Analysis / the Share Price Launched - IDMC UNBLINDED ACTUAL MOS AND IR DATA at 60 EVENTs*** - Dec 26th 2025 - 72nd Event PR / Share Price Launched 136 Days Later / 6 Events / 1 event every 22 Days - May 11 78th Event PR / Share Price Launched its now been 50 Days Since the 78th Event / an event every 22 Days The 80th EVENT PR is NOW IMMINENT and WILL Launch the Share Price, ahead of the Massively Valuable Phase 3 Registrational Results - 5 years in the making - giving GPs the FDA Green light to treat upwards of 40,000 AML Remission Patients Each year / A FDA Green Light to generate 10's of Billions of Dollars in REAL REVENUE - worth Every Nickel of $40B to Big Pharma --- How Long is too Long to Wait for a 10x / 20x ROI Opportunity?
6 · Reply
t_augs1
t_augs1 Jun. 29 at 11:22 PM
$ABBV $ABBV the past three months! LFG…
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 8:13 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:54 PM
$SLS $GILD $ABBV What's really F'd Up Here - is the real investors who've loaded in here - Know - SLS Could Announce a Sale of SLS009 - the Secondary Asset - for $7B and noone would blink an eye. - just the secondary asset, SLS009 is worth at least $5 to $7B - $25 -$30 per share, right now. SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B...
0 · Reply
BarbaraSmith247
BarbaraSmith247 Jun. 29 at 7:50 PM
$ABBV trading around 255.30 today. Seeing some action on the pipeline front with trial milestones and regulatory opinions, which is keeping the sentiment constructive. Still, not looking to force a trade at these levels. Patience is the play.
0 · Reply